Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.46 |
| ▸ | RXRG | P48443 | 8/20 | 0.46 |
| ▸ | RXRB | P28702 | 7/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 5/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156575 | 0.91 | PTGDR2 (0.49) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL137643 | 0.89 | CETP (0.40) | RXRARXRGRXRBPTGDR2TACR1 | |
| SCHEMBL138141 | 0.85 | PTGDR2 (0.37) | RXRARXRGRXRBPTGDR2AKR1C3 | |
| SCHEMBL137634 | 0.83 | PTGS2 (0.44) | PTGDR2 | |
| SCHEMBL152827 | 0.83 | PTGDR2 (0.48) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL155458 | 0.82 | PTGDR2 (0.47) | RXRARXRGRXRBPSEN1PSEN2 | |
| SCHEMBL137601 | 0.81 | GPBAR1 (0.46) | RXRARXRGRXRBPTGDR2CETP | |
| SCHEMBL135943 | 0.81 | AKR1C3 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL137059 | 0.81 | AKR1C3 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL134922 | 0.81 | PTPN11 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-8362044-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058123-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | RXRA 767/4885RXRG 403/4885RXRB 492/4885 |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | RXRA 767/4885RXRG 403/4885RXRB 492/4885 |
| US-20120058123-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | RXRA 767/4885RXRG 403/4885RXRB 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.